Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial PharmaphorumRoche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.OncologyRead full story pharminent July 2, 2026 (Last updated: July 2, 2026) Pharmaphorum Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib. Oncology Read full story Post navigation Previous: Insilico Medicine, Takeda partner on AI-driven drug discoveryNext: AZ forges ever-closer ties with China’s CSPC Pharma Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026